191 results on '"Gee, Adrian P."'
Search Results
2. Environmental oxygen affects ex vivo growth and proliferation of mesenchymal progenitors by modulating mitogen-activated protein kinase and mammalian target of rapamycin signaling
3. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified IECs
4. Clinical effects of administering leukemia-specific donor T cells to patients with AML/MDS after allogeneic transplant
5. Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients: The CCTRN SENECA Trial
6. “Mini” bank of only 8 donors supplies CMV-directed T cells to diverse recipients
7. Safety and feasibility of virus-specific T cells derived from umbilical cord blood in cord blood transplant recipients
8. In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin’s Lymphomas
9. EBV/LMP-specific T cells maintain remissions of T- and B-cell EBV lymphomas after allogeneic bone marrow transplantation
10. Rationale and Design of the SENECA (StEm cell iNjECtion in cAncer survivors) Trial
11. GMP CAR-T cell production
12. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma
13. International Society for Cellular Therapy perspective on immune functional assays for mesenchymal stromal cells as potency release criterion for advanced phase clinical trials
14. Quantitative activation suppression assay to evaluate human bone marrow–derived mesenchymal stromal cell potency
15. Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation
16. A reproducible immunopotency assay to measure mesenchymal stromal cell–mediated T-cell suppression
17. Clinical and immunological responses after CD30-specific chimeric antigen receptor-redirected lymphocytes
18. Efficient manufacturing of therapeutic mesenchymal stromal cells with the use of the Quantum Cell Expansion System
19. Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene
20. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15
21. Optimizing the production of suspension cells using the G-Rex “M” series
22. TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function: Final 2-Year Analysis
23. Clinical responses with T lymphocytes targeting malignancy-associated κ light chains
24. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study
25. Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation
26. Manufacturing mesenchymal stromal cells for phase I clinical trials
27. Large-scale ex vivo expansion and characterization of natural killer cells for clinical applications
28. Production of good manufacturing practice-grade cytotoxic T lymphocytes specific for Epstein–Barr virus, cytomegalovirus and adenovirus to prevent or treat viral infections post-allogeneic hematopoietic stem cell transplant
29. Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
30. Good manufacturing practice-grade cytotoxic T lymphocytes specific for latent membrane proteins (LMP)-1 and LMP2 for patients with Epstein–Barr virus-associated lymphoma
31. HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer
32. Adverse events following infusion of T cells for adoptive immunotherapy: a 10-year experience
33. Multicenter cell processing for cardiovascular regenerative medicine applications: the Cardiovascular Cell Therapy Research Network (CCTRN) experience
34. Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantation
35. Effect of graft source on unrelated donor haemopoietic stem-cell transplantation in adults with acute leukaemia: a retrospective analysis
36. CD34+ cell selection using small-volume marrow aspirates: a platform for novel cell therapies and regenerative medicine
37. The Effect of the Composition of Unrelated Donor Bone Marrow and Peripheral Blood Progenitor Cell Grafts on Transplantation Outcomes
38. Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation
39. Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopes
40. Cell therapy product administration and safety: data capture and analysis from the Production Assistance for Cellular Therapies (PACT) program
41. Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patients
42. Rapid Transport and Infusion of Hematopoietic Cells Is Associated with Improved Outcome after Myeloablative Therapy and Unrelated Donor Transplant
43. Nerve Growth Factor: Stimulation of Polymorphonuclear Leukocyte Chemotaxis in vitro
44. CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients
45. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
46. Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transfer
47. Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals
48. Peripheral Blood Grafts from Unrelated Donors Are Associated with Increased Acute and Chronic Graft-versus-Host Disease without Improved Survival
49. Treatment of solid organ transplant recipients with autologous Epstein Barr virus–specific cytotoxic T lymphocytes (CTLs)
50. Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantation
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.